Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) Shares Shorted: Short Interest Down 50.2% in September

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totaling 947,657 shares, a drop of 50.2% from the September 15th total of 1,904,283 shares. Approximately 11.7% of the company’s shares are short sold. Based on an average trading volume of 26,546,756 shares, the short-interest ratio is presently 0.0 days.

Mymd Pharmaceuticals Stock Up 3.3%

NASDAQ QCLS traded up $0.02 during trading on Thursday, reaching $0.56. 131,888 shares of the company’s stock were exchanged, compared to its average volume of 2,114,455. Mymd Pharmaceuticals has a fifty-two week low of $0.42 and a fifty-two week high of $8.17. The company has a market capitalization of $4.57 million, a price-to-earnings ratio of -0.16 and a beta of 2.32. The stock has a fifty day moving average price of $1.63.

Mymd Pharmaceuticals (NASDAQ:QCLS) last released its earnings results on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on QCLS. Weiss Ratings restated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. Wall Street Zen raised shares of Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Mymd Pharmaceuticals currently has an average rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases, inflammation and age-related conditions. The company has historically pursued treatments designed to regulate the immune system and address biological processes associated with chronic disease and aging.

MyMD’s principal investigational product has been MYMD-1, an orally administered small-molecule therapy intended to modulate immune and inflammatory responses.